Volume 5.42 | Nov 4

Newsletter Issue
Hematopoiesis News 5.42 November 4, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Ischemic Stroke Activates Hematopoietic Bone Marrow Stem Cells
Scientists tested the hypothesis that transient middle cerebral artery occlusion (tMCAO) in mice leads to activation of hematopoietic bone marrow stem cells. Serial in vivo bioluminescence reporter gene imaging in mice with tMCAO revealed that bone marrow cell cycling peaked four days after stroke. [Circ Res] Abstract
View Data: UM729, a Novel Small Molecule for Ex Vivo Expansion of Human hSCs
PUBLICATIONS (Ranked by impact factor of the journal)
Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia
Using the Mx1-Cre transgene to inactivate a conditional mutant Nras allele, investigators analyzed hematopoiesis and hematopoietic stem and progenitor cells (HSPC) under normal and stressed conditions and found that HSPCs lacking Nras expression are functionally equivalent to normal HSPCs in the adult mouse. [Blood] Abstract

IFN-γ Causes Aplastic Anemia by Altering Hematopoiesis Stem/Progenitor Cell Composition and Disrupting Lineage Differentiation
Since IFN-γ can be detected in peripheral blood mononuclear cells of aplastic anemia (AA) patients, it has been hypothesized that autoreactive T lymphocytes may be involved in destroying the hematopoietic stem cells. Investigators observed AA-like symptoms in their IFN-γ AU-rich element – deleted mice which constitutively express a low level of IFN-γ under normal physiologic conditions. [Blood] Abstract

TGIF1 Is a Negative Regulator of MLL-Rearranged Acute Myeloid Leukemia
TGIF1/TGIF2 are relatively uncharacterized TALE (three-amino acid loop extension) transcription factors, which in contrast to the remaining family, have been shown to act as transcriptional repressors. Given the general importance of this family in malignant hematopoiesis scientists tested the potential function of TGIF1 in the maintenance of mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia. [Leukemia] Abstract

Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis-I
Researchers demonstrate defective WT hematopoietic stem and progenitor cell engraftment and migration in Idua-/- recipient bone marrow, particularly under reduced intensity conditioning. [J Biol Chem]
Abstract | Full Article

Foxp3+ Regulatory T Cells Ensure B Lymphopoiesis by Inhibiting the Granulopoietic Activity of Effector T Cells in Mouse Bone Marrow
Scientists found that Foxp3 mutant scurfy mice had fewer B-lineage cells and progenitors, including common lymphoid progenitors and lymphoid-primed multipotent progenitors, but higher myeloid-lineage cell numbers in bone marrow compared with wild-type littermates. Homeostasis within the hematopoietic stem cell compartment was also compromised with apparent expansion of long- and short-term hematopoietic stem cells. [Eur J Immunol] Abstract

ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML
Investigators performed transcriptome analysis on primitive CD34+ acute myeloid leukemia (AML) cells, their more differentiated CD34 leukemic progeny, and normal CD34+ bone marrow cells and focused on differentially expressed genes involved in adhesion and migration. [PLoS One] Full Article


Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Based on CIBMTR registry data, researchers investigated chronic graft-versus-host disease and its association with the incidence of late relapse and survival in 7489 patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and myelodysplastic syndromes who were leukemia-free at 12 months after myeloablative allogeneic hematopoietic cell transplantation. [Clin Cancer Res] Abstract

Intermediate Doses of Cytarabine plus Granulocyte-Colony-Stimulating Factor as an Effective and Safe Regimen for Hematopoietic Stem Cell Collection in Lymphoma Patients with Prior Mobilization Failure
Researchers report on 33 patients diagnosed with lymphoma who had at least one prior mobilization failure and received cytarabine at a dose of 400 mg/m2/day intravenously × three days plus granulocyte-colony-stimulating factor 10 to 12 μg/kg/day as mobilization regimen. [Transfusion] Abstract

How Ex Vivo Models Drive Progress in HIV Research: Read the Research Profiles
Antibody- and Aptamer-Strategies for GvHD Prevention
The authors focus on murine models for graft-versus-host-disease (GvHD) and currently available treatment options involving antibodies and applications for the therapeutic use of aptamers as well as strategies for targeting immune responses by allogenic antigens. [J Cell Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
BioLineRx Files Protocol Amendment to Phase II Study for AML Treatment Based on Encouraging Efficacy and Strong Safety Profile
BioLineRx Ltd. announced that in light of encouraging pharmacodynamic and excellent safety data from the ongoing Phase II clinical trial of BL-8040 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), the company has filed with the U.S. Food and Drug Administration an amendment to the study protocol to test additional cohorts at higher doses in the current dose-escalation stage of the trial. [BioLineRx Ltd.] Press Release

HEMACORD®, the First FDA-Licensed Stem Cell Product, Wins Prix Galien USA “Best Biotechnology Product” Award
The New York Blood Center’s Milstein National Cord Blood Program announced that HEMACORD®, the first FDA-licensed hematopoietic stem cell product, has been awarded the prestigious “Best Biotechnology Product” Award by Prix Galien USA. [New York Blood Center] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell & Gene Therapy Forum 2015
January 26-28, 2015
Washington DC, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Position – Post-Transcriptional Control of Gene Expression in Hematopoietic Stem Cells (Lund University)

NEW Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

NEW PhD Studentship – Discovery of Key Regulators of Normal and Leukemic Stem Cell Functions (University of Edinburgh)

Postdoctoral Position – NK Cell and Leukemia Research (Children’s Hospital Los Angeles)

Postdoctoral Research Associate – Mechanisms Underlying Hematopoiesis and Leukemogenesis (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Position – Regenerative Effects of Some Mutations on Hematopoietic Stem Cells (Istanbul University Institute of Experimental Medicine)

Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us